
    
      This is a multi-center, randomized, double-blind, placebo-controlled study designed to
      investigate the safety and efficacy of a single injection of COVI-AMG in inpatient adults
      with COVID-19. Subjects will receive 100 mg of COVI-AMG, 200 mg of COVI-AMG, or placebo via
      slow IV push. Subjects will be followed for approximately 70 days post dosing.
    
  